Single-photon emission computed tomography (SPECT) enables non-invasive visualization of gamma-emitting radiopharmaceuticals within living systems, providing critical insights into biodistribution, target engagement, and therapeutic agent accumulation. Protheragen delivers integrated SPECT imaging study services spanning preclinical tracer characterization through IIT clinical investigations to advance your radiopharmaceutical pipeline.
Single-photon emission computed tomography (SPECT) is a nuclear medicine imaging technique that detects gamma-ray photons emitted by radiolabeled compounds to generate three-dimensional maps of radiopharmaceutical distribution within biological tissues. By utilizing radionuclides such as technetium-99m, iodine-123, iodine-131, indium-111, and lutetium-177, SPECT provides functional molecular information that reveals receptor density, metabolic activity, and drug-target interactions across diverse disease models. When integrated with computed tomography (SPECT/CT), this modality combines functional sensitivity with anatomical precision, enabling accurate localization of tracer uptake and quantitative assessment of organ-level distribution.
Fig 1. Basic principles and components of a modern gamma camera. (Alqahtani, Fawaz F, et al., 2023)
SPECT imaging offers distinct advantages in radiopharmaceutical development, including the ability to simultaneously visualize multiple radiotracers differentiated by their gamma emission energies, broader availability of generator-produced isotopes such as Tc-99m, and lower operational costs compared to positron-emitting alternatives. These characteristics make SPECT particularly valuable for longitudinal biodistribution studies, patient-specific dosimetry calculations, and the monitoring of therapeutic radiopharmaceutical distribution in both preclinical models and clinical settings. The technique supports critical decision points from lead compound selection through first-in-human trial design.
The theranostic paradigm—pairing diagnostic imaging with matched targeted radionuclide therapy—has positioned SPECT/CT as an indispensable tool for treatment planning and response monitoring. SPECT/CT enables real-time visualization of therapeutic agent distribution, quantitative organ-level dosimetry, and longitudinal assessment of tumor uptake for gamma-emitting isotopes. The table below summarizes key theranostic applications where SPECT/CT plays a central role in both preclinical development and clinical translation.
| Theranostic Pair | Diagnostic SPECT Tracer | Therapeutic Counterpart | Clinical Application |
|---|---|---|---|
| SSTR | 111In-DTPA-octreotide / 99mTc-HYNIC-TOC | 177Lu-DOTATATE | Neuroendocrine tumors |
| PSMA | 99mTc-MIP-1404 | 177Lu-PSMA-617 / 225Ac-PSMA-617 | Prostate cancer |
| Thyroid | 123I / 131I whole-body scan | 131I-NaI | Differentiated thyroid cancer |
| Bone metastases | 99mTc-MDP bone scan | 223RaCl2 | Castration-resistant prostate cancer |
| FAP | 99mTc-FAPI-46 | 177Lu-FAPI-46 | Solid tumors |
| Neuroblastoma | 123I-MIBG | 131I-MIBG | Pediatric neuroblastoma |
Protheragen offers a comprehensive SPECT imaging study platform designed to support radiopharmaceutical developers from early-stage tracer evaluation through clinical translation. Our integrated preclinical and clinical infrastructure encompasses radiochemistry, quantitative SPECT/CT imaging, biodistribution analysis, and dosimetry modeling—enabling seamless progression from proof-of-concept studies to regulatory-compliant clinical trial support under GCP and GLP frameworks.
Small-animal SPECT/CT imaging for biodistribution, tumor targeting, and pharmacokinetic assessment using Tc-99m, I-123, I-131, In-111, and Lu-177 radiolabels. Dynamic and static acquisition protocols support quantitative analysis of tracer uptake, clearance kinetics, and off-target accumulation in rodent and non-rodent models.
Custom radiolabeling of small molecules, peptides, antibodies, and engineered fragments with gamma-emitting isotopes. GMP-compliant precursor synthesis, quality control, and stability testing ensure traceability from preclinical evaluation to clinical manufacturing.
Whole-body quantitative SPECT/CT imaging combined with ex vivo gamma counting to generate time-activity curves, organ-level absorbed dose estimates, and dose-volume histograms. These data inform safety margins and optimize therapeutic dosing regimens for first-in-human trials.
Microdosing SPECT studies for human pharmacokinetic assessment, receptor occupancy quantification, and target engagement validation. Integration with established radiotracers enables metabolic monitoring and treatment response evaluation across oncology, cardiology, and neurology indications.
Design and validation of SPECT imaging biomarkers co-developed with therapeutic radiopharmaceuticals. Supports regulatory submission packages for diagnostic-therapeutic pairing under the theranostic framework, including IND/IMPD documentation.
Phase 0, Phase I, and Phase II SPECT/CT protocol design, site qualification, image acquisition, centralized analysis, and clinical study report preparation. GCP-compliant workflows with standardized operating procedures and radiation safety oversight.
Protheragen combines deep radiopharmaceutical expertise with a fully integrated SPECT imaging infrastructure to deliver high-quality quantitative data that accelerate development timelines and reduce program risk.
Ready to advance your radiopharmaceutical development with precision SPECT imaging? Contact us today to discuss your project requirements, or reach out to our scientific team for a customized study proposal tailored to your therapeutic pipeline.
Reference